The DESyne BD NECSS demonstrated non-inferiority and superiority over Endeavor for in-stent late lumen loss at 6 months. Clinical events remained low through 24 months; clinical results through 36 months will be presented.
Background: The multicenter, prospective, randomized, single-blinded, investigatorinitiated DUTCH PEERS (TWENTE II) "All Comers" Trial demonstrated at 1-year follow-up the non-inferiority of third-generation Resolute Integrity zotarolimuseluting stents (Medtronic Vascular, Santa Rosa, CA) versus Promus Element everolimus-eluting stents (Boston Scientific, Natick, MA), based on a similar incidence of the primary endpoint target vessel failure (TVF), a composite of cardiac death, target vessel revascularization (TVR), or myocardial infarction (MI) . No other follow-up data beyond 12 months have been published from a randomized head-to-head comparison of both stents. Methods: In 4 study centers in the Netherlands, 1,811 patients were 1:1 randomly assigned to treatment with one of both stents. Patients with any clinical syndrome, any lesion type, and any number of lesions or vessels to be treated were included. Study monitoring and clinical event adjudication were performed by two independent Dutch contract research organizations (Diagram, Zwolle, and Cardialysis, Rotterdam, respectively) . Results: DUTCH PEERS examines an all-comer patient population that included 59% of patients with acute coronary syndromes (20% of all patients presented with an acute STEMI) and 66% of patients with complex target lesions. We will compare for both stent groups the 2-year incidence of TVF (primary endpoint) and various secondary endpoints, including individual components of the primary endpoint, the incidence of stent thrombosis, and other composite endpoints, such as target lesion failure, major adverse cardiac events, and the patient-oriented composite endpoint. In addition, we will report the outcome of patients with longitudinal stent deformation after discontinuation of dual anti-platelet therapy. Conclusions: Clinical outcome of the DUTCH PEERS trial at 2-year follow-up will be presented.
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Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in diabetic patients: 5 year follow up from the COMPARE I trial Background: Long-term comparison data of the current generation everolimuseluting stent (XienceÔ V; EES) with the first generation paclitaxel-eluting stent (TaxusÔ Liberté; PES) in an all-comers diabetic cohort undergoing percutaneous coronary intervention (PCI) are scarce. Initial results at 2 year follow-up indicated no differences in clinical outcomes between the two stent types in diabetic patients. Methods: The COMPARE I study was a prospective, randomized, single-center, allcomer trial randomly allocating (1:1) patients to receive either EES or PES. It is to date the only randomized trial comparing EES to PES in a true all-comers population with an independent adjudicated 5-year follow-up. Randomization was stratified by the presence of diabetes. The primary endpoint was major adverse cardiovascular events (MACE) defined as the composite of the safety endpoints death or myocardial infarction (MI) and the efficacy endpoint target vessel revascularization (TVR). Results: Of the 1800 study patients, 325 patients were diabetic (18.1%) of whom 153 were treated with EES and 172 with PES. At 5 years EES reduced MACE compared to PES in non-diabetic patients (17.1% vs. 23.0%, p< 0.01) with significant reduction in MI (6.6% vs. 11.1%, p< 0.01), TVR (7.0% vs. 10.4%, p¼0.02), and definite or probable stent thrombosis (2.6% vs. 5.5%, p< 0.01). In the diabetic patients, EES compared to PES reduced MACE (24.8% vs. 34.3%, p¼0.06) and TVR (9.2% vs. 15.7%, p¼0.08) without reaching statistical significance. The 5 year outcomes are tabulated. Background: We sought to investigate the long-term outcomes of an abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort Medical, Shanghai, China) compared to an everolimus-eluting stent (EES) XIENCE V in the randomized TARGET I trial. Methods: A total of 458 patients with single de novo native coronary lesions < ¼24 mm in length and a coronary artery >¼2.25 to < ¼4.0 mm in diameter were enrolled in the TARGET I study, a prospective, randomized, non-inferiority trial. The primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary endpoint, target lesion failure (TLF), was defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6-and 12-month, and annually up to 5 years for all enrolled patients. All adverse clinical events were adjudicated by an independent committee. Results: Previously reported results demonstrated FIREHAWK stent was non-inferior to XIENCE V EES for the primary endpoint of 9-month in-stent LLL (0.13AE0.24 mm vs. 0.13AE0.18 mm, p¼0.94; difference and 95% confidence interval 0.00 [-0.04, 0.04] mm; p for non-inferiority < 0.0001), and had a comparable clinical outcome at 2 years. There were still no significant differences between the two groups up to 3 years, and no definite/probable stent thrombosis occurred in FIREHAWK group. (Table) Conclusions: In the multicenter randomized TARGET I trial, the 3-year follow-up results confirmed that the novel FIREHAWK stent had a durable safety and efficacy profile, which was comparable to the XIENCE V EES for the treatment of Kyoto University, Kyoto, Japan Background: Drug-eluting stents with biodegradable polymers have been developed to reduce the risk of very late adverse events. Distinct studies have indicated noninferiority of the biodegradable polymer-coated biolimus-eluting stent (NoboriÔ; BES) compared to the durable polymer-coated everolimus-eluting stent (XienceÔ or PromusÔ; EES) with regards to safety and efficacy at 1 year. However, these trials were not powered to detect differences in low-frequency events. Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned 5942 patients to BES or EES and is at present the largest pooled analysis of BES in all-comers requiring percutaneous coronary intervention (PCI). The pre-specified composite endpoint was target vessel failure (TVF) defined as cardiac death, target vessel related myocardial infarction (MI), or clinical-indicated target vessel revascularization (TVR-CD).
Results: The pooled unadjusted 1-year clinical outcomes of the 5942 study patients (8094 lesions) are tabulated. Covariate adjusted analyses accounting for baseline imbalances between trials confirmed non-significant differences between stent type and clinical outcomes. The trend for a higher definite stent thrombosis rate in the BES group was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60]; p¼0.16).
Conclusions: At 1-year the biodegradable polymer-coated BES has similar safety and efficacy outcomes as the durable polymer-coated EES. Longer follow-up data is needed to determine the role of biodegradable polymer-coated BES in real world clinical practice. Background: These are the first long-term randomized adjudicated trial data of five year results of the Genous bio-engineered endothelial progenitor cell capturing stent (OrbusNeich BV, Fort Lauderdale, FL, USA) compared with a paclitaxel-eluting stent(PES). Methods: In this prospective randomized trial, patients with de-novo coronary artery lesions carrying a high risk of restenosis (chronic total occlusion,lesion length > 23mm,vessel diameter < 2.8mm or any lesion in a diabetic patient) were randomized 1:1 to the Genous or a PES. The current primary endpoint is adjudicated target vessel failure (TVF) at 5-years, a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization. Clinical event rates were estimated by Kaplan-Meier method and compared with a log-rank test. Results: A total of 193 patients were included with complete follow-up in 97% of the subjects. The primary endpoint of TVF was similar at 5 years with Genous 23.8% vs 
